Manchester, 9 September 2009. DxS Ltd, a personalised medicine company and leader in the provision of companion diagnostics, has today announced the appointment of Dr. Patrik Dahlen as non-executive director. As the former CEO of global cancer diagnostics company Dako, Dr. Dahlen will bring invaluable industry insight and a fresh persepective to DxS during the company’s continued period of expansion.

Dr. Dahlen has occupied high level positions within the diagnostics and life sciences sector for over 15 years. Prior to his four year tenure at Dako from 2005 to January 2009 Dr. Dahlen was CEO of the Danish biotech company Biolmage and previous to that president of lifesciences and senior vice president at PerkinElmer. Dr. Dahlen currently holds other board positions which include Proxeon and Olink and has been a board member for DakoCytomation and Cantion.

Commenting on his appointment, Dr. Dahlen said: “I am delighted to be joining DxS as a non-executive director. DxS is an exciting company in a very strong growth phase, and I believe that my experience in cancer diagnostics and companion diagnostics will further benefit the company."

Dr. Stephen Little, CEO of DxS said: “Patrik is a well respected figure in the sphere of cancer diagnostics with a great knowledge of the industry. His extensive expertise will be invaluable as DxS continues to expand and evolve.”

Dr. Dahlen’s appointment is part of DxS’ continuing plan for growth, which has seen the company more than double in size within the last twelve months with new manufacturing space taken on their Manchester site. In 2008 DxS signed a global distribution agreement with Roche Molecular Diagnostics for their TheraScreen® brand of diagnostics kits, and a deal which seen Amgen and Merck Serono/Bristol Myers Squibb use DxS’ TheraScreen: K-RAS Mutation Kit as a companion diagnostic for the colorectal cancer treatment Vectibix® and Eribitx®. In May DxS announced a deal with Boehringer Ingleheim to provide a companion diagnostic test kit for BIBW 2992 (Tovok™), and in July a deal with AstraZeneca to develop a companion diagnostic for use with IRESSA™(gefitinib).